3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Opioid-Related Disorders
1
Neoplasms
1
Lymphoma, Follicular
1
Cancer Pain
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
3
Nivolumab
2
temoporfin
1
spartalizumab
1
polysaccharide-K
1
pembrolizumab
1
nimotuzumab
1
devimistat
1
dalotuzumab
1
bemarituzumab
1
belinostat
1
Transurethral Resection of Prostate
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiofrequency Ablation
1
Oxaliplatin
1
Morphine
1
Methadone
1
Leucovorin
1
Ipilimumab
1
Interviews as Topic
1
Injections
1
Immunotherapy
1
Heavy Ion Radiotherapy
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cryosurgery
1
Cisplatin
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma
×
Methadone
×
Clear all
NCT05325164
2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3
Withdrawn